Grants and Contributions

• Accelerate the availability of high-quality and real-time evidence to support Canada’s rapid response to the global pandemic in order to better prevent, detect, treat and manage COVID-19;
• Develop, test, and study the implementation of effective interventions to prevent, detect, treat, and manage COVID-19 at the individual and/or population levels by reorienting or amplifying existing research platforms, networks, and trials as well as funding new research projects within existing and established research infrastructure;
• Enable Canadian engagement and coordination in national and international large-scale trials and better enable harmonized data collection, sharing of data, quasi-experimental and observational studies, and rapid large-scale evaluation of impact;
• Provide evidence to inform clinical and health system management and public health response, and/or decision-making and planning within and across jurisdictions in Canada and internationally; and
• Enhance local, national and/or international collaborative efforts, including in low- and middle-income countries, to mitigate the rapid spread of COVID-19 and related negative consequences.

• Accelerate the availability of high-quality and real-time evidence to support Canada’s rapid response to the global pandemic in order to better prevent, detect, treat and manage COVID-19;
• Develop, test, and study the implementation of effective interventions to prevent, detect, treat, and manage COVID-19 at the individual and/or population levels by reorienting or amplifying existing research platforms, networks, and trials as well as funding new research projects within existing and established research infrastructure;
• Enable Canadian engagement and coordination in national and international large-scale trials and better enable harmonized data collection, sharing of data, quasi-experimental and observational studies, and rapid large-scale evaluation of impact;
• Provide evidence to inform clinical and health system management and public health response, and/or decision-making and planning within and across jurisdictions in Canada and internationally; and
• Enhance local, national and/or international collaborative efforts, including in low- and middle-income countries, to mitigate the rapid spread of COVID-19 and related negative consequences.

Canada’s support to Gavi, the Vaccine Alliance will assist in the realisation of Gavi’s Strategic Plan for 2016-2020, which aims to save 5-6 million children’s lives through equitable use of vaccines in lower income countries. Approximately 80% of these funds will be provided to procure and deliver vaccines requested by countries for their national immunizations programs.

Support provided to the International Society for Vaccines, the world's largest non-commercial, scientific conference for basic and clinical researchers interested in vaccines and underlying sciences.

To be eligible to the competition, applications must address ALL objectives AND key design components:

• Establish central coordination and collaboration activities with Collaborating Sites located across Canada to increase the availability of high-quality and real-time evidence to support research on the effectiveness and relative safety of the COVID-19 vaccines in children and youth;
• Generate research evidence related to COVID infection and vaccination in diverse children and youth population(s), including (but not limited to):
o Equity considerations;
o Health and well-being status (e.g., historically excluded or underserved populations, individuals with complex health needs and/or a disability);
o Sex and gender; and/or
o Racialized and Indigenous (First Nations, Inuit, Métis and Urban Indigenous) populations.
• Identify children and youth populations at the highest and high risk for negative outcomes related to COVID-19 vaccination, and other determinant of health factors (e.g., social, economic, behaviour, etc.) that are associated with this increased greater risk.
• Harmonize data collection, and improve open and real-world data sharing with relevant knowledge-users in an accessible, useful and relevant format to support a timely and effective COVID-19 public health response within and across all jurisdictions in Canada as it relates to children and youth;
• Collaborate across Sites to establish resource and data sharing policies, increase efficiencies in research and related processes (including but not limited to ethics review; privacy considerations; contracts; informed-consent; common protocols; developing applications for trial funding; consistent and valid patient-oriented outcomes), reduce duplication, and maximize research and surveillance activities related to COVID-19 vaccination of children and youth; and
• Provide research evidence to inform clinical and health system management and public health response, and/or decision-making and planning within and all across jurisdictions in Canada and internationally.

Towards rational design of Salmonella vaccin

Towards a Universal Influenza Virus Vaccine

Facilitate a GMP clinical vaccine manufacture

The intern would assist with calving vaccinating, feeding, weaning, hauling to pasture and back in the fall and building new fence.

The purpose of the funding will be to support a feasibility assessment and detailed engineering design for the expansion of Therapure’s current mammalian cell culture (MCC) capacity in support of VBI’s coronavirus vaccine as well as other MCC projects and coronavirus vaccines that require insect cell/baculovirus expression systems and potentially adeno viral vectors. The two areas at Therapure’s current biomanufacturing facility that will be assessed to support pandemic vaccine manufacturing:

•Existing space within the facility
•Extension of the existing space with access to some of the existing utilities and all other systems such as Quality, Project Management, Finance and IT